Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat

Skin Laxity Clinical Trial

Official title:

Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental Fat

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05831332
• Other study ID #: BTL-785_CTBG200
• Status: Completed
• Phase: N/A
• Start date: March 6, 2023
• Est. completion date: October 25, 2023

Study information

• Verified date: October 2023
• Source: BTL Industries Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: October 25, 2023
• Est. primary completion date: August 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Healthy male or female subjects over 21 years of age seeking treatment for reduction of submental fat

• Subjects should be able understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form

• Presence of clearly visible excess fat in submentum as deemed appropriate by the Investigator

• Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation

• Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken

Exclusion Criteria:

• Local bacterial or viral infection in the area to be treated

• Local acute inflammation in the area to be treated

• Impaired immune system caused by any immunosuppressive illness, disease or medication

• Isotretinoin and tretinoin-containing medication use in the past 12 months

• Skin related autoimmune diseases

• Radiation therapy and/or chemotherapy

• Poor healing and unhealed wounds in the treatment area

• Metal implants

• Permanent implant in the treated area

• Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body

• Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment

• Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles

• History of skin disorders, keloids, abnormal wound healing and dry or fragile skin

• History of any type of cancer

• Active collagen diseases

• Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)1

• Pregnancy/nursing or IVF procedure

• History of bleeding coagulopathies, use of anticoagulants

• Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea

• Any surgical procedure in the treatment area within the last three months or before complete healing

• Poorly controlled endocrine disorders, such as diabetes

• Acute neuralgia and neuropathy

• Kidney or liver failure

• Nerve insensitivity (sensitivity disorders) to heat in the treatment area

• Varicose veins, pronounced edemas1

• Prior use of dermal fillers, botulinum toxin, lasers, etc. therapies in the treated area that can influence the study results at the investigator discretion

• Unwillingness/inability to not change their usual cosmetics and especially not to use fat reduction, anti-aging or anti-wrinkles products in the treated area during the duration of the study including the follow-up period

• Electroanalgesia without exact diagnosis of pain etiology

• Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)

• Blood vessels and lymphatic vessels inflammation

• Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study

Related Conditions & MeSH terms

• Cutis Laxa
• Skin Laxity

Intervention

Device:
• BTL-785-7
Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.

Locations

Country	Name	City	State
Bulgaria	Center for specialized medical care - Individual dermatological practice Dr. Mariya Genova	Plovdiv

Sponsors (1)

Lead Sponsor	Collaborator
BTL Industries Ltd.

Country where clinical trial is conducted

Bulgaria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of submental fat thickness	To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide reduction of submental fat thickness.	6 months
Secondary	Evaluation the effect on submental skin laxity	To gather clinical evidence that BTL-785F system equipped with BTL-785-7 applicator is able to provide improved skin laxity in the submental area.	6 months
Secondary	Evaluation the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat.	To evaluate the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat through monitoring of adverse reactions.	6 months